PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jvirolPermissionsJournals.ASM.orgJournalJV ArticleJournal InfoAuthorsReviewers
 
J Virol. 1996 June; 70(6): 3724–3733.
PMCID: PMC190248

Vaccine protection by a triple deletion mutant of simian immunodeficiency virus.

Abstract

Twelve rhesus monkeys were vaccinated with SIVmac316 delta nef (lacking nef sequences), and 12 were vaccinated with SIVmac239 delta3 (lacking nef, vpr, and upstream sequences in U3). SIVmac316 and SIVmac239 differ by only eight amino acids in the envelope; these changes render SIVmac316 highly competent for replication in macrophages. Seventeen of the animals developed persistent infections with the vaccine viruses. Seven of the 24 vaccinated animals, however, developed infections that were apparently transient in nature. Six of these seven yielded virus from peripheral blood when tested at weeks 2 and/or 3, three of the seven had transient antibody responses, but none of the seven had persisting antibody responses. The 24 monkeys were challenged in groups of four with 10 rhesus monkey infectious doses of wild-type, pathogenic SIVmac251 at weeks 8, 20, and 79 following receipt of vaccine. None of the seven with apparently transient infections with vaccine virus were protected upon subsequent challenge. Analysis of cell-associated viral loads, CD4+ cell counts, and viral gene sequences present in peripheral blood in the remainder of the monkeys following challenge allowed a number of conclusions. (i) There was a trend toward increased protection with length of time of vaccination. (ii) Solid vaccine protection was achieved by 79 weeks with the highly attenuated SIV239 delta3. (iii) Solid long-term protection was achieved in at least two animals in the absence of complete sterilizing immunity. (iv) Genetic backbone appeared to influence protective capacity; animals vaccinated with SIV239 delta3 were better protected than animals receiving SIV316 delta nef. This better protection correlated with increased levels of the replicating vaccine strain. (v) The titer of virus-neutralizing activity in serum on the day of challenge correlated with protection when measured against a primary stock of SIVmac251 but not when measured against a laboratory-passaged stock. The level of binding antibodies to whole virus by enzyme-linked immunosorbent assay also correlated with protection.

Full Text

The Full Text of this article is available as a PDF (627K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Ahmad S, Lohman B, Marthas M, Giavedoni L, el-Amad Z, Haigwood NL, Scandella CJ, Gardner MB, Luciw PA, Yilma T. Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus. AIDS Res Hum Retroviruses. 1994 Feb;10(2):195–204. [PubMed]
  • Almond N, Kent K, Cranage M, Rud E, Clarke B, Stott EJ. Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet. 1995 May 27;345(8961):1342–1344. [PubMed]
  • Arthur LO, Bess JW, Jr, Urban RG, Strominger JL, Morton WR, Mann DL, Henderson LE, Benveniste RE. Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus. J Virol. 1995 May;69(5):3117–3124. [PMC free article] [PubMed]
  • Burns DP, Collignon C, Desrosiers RC. Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys. J Virol. 1993 Jul;67(7):4104–4113. [PMC free article] [PubMed]
  • Clerici M, Clark EA, Polacino P, Axberg I, Kuller L, Casey NI, Morton WR, Shearer GM, Benveniste RE. T-cell proliferation to subinfectious SIV correlates with lack of infection after challenge of macaques. AIDS. 1994 Oct;8(10):1391–1395. [PubMed]
  • Cranage MP, Polyanskaya N, McBride B, Cook N, Ashworth LA, Dennis M, Baskerville A, Greenaway PJ, Corcoran T, Kitchin P, et al. Studies on the specificity of the vaccine effect elicited by inactivated simian immunodeficiency virus. AIDS Res Hum Retroviruses. 1993 Jan;9(1):13–22. [PubMed]
  • Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science. 1992 Dec 18;258(5090):1938–1941. [PubMed]
  • Daniel MD, Letvin NL, Sehgal PK, Hunsmann G, Schmidt DK, King NW, Desrosiers RC. Long-term persistent infection of macaque monkeys with the simian immunodeficiency virus. J Gen Virol. 1987 Dec;68(Pt 12):3183–3189. [PubMed]
  • Daniel MD, Sehgal PK, Kodama T, Wyand MS, Ringler DJ, King NW, Schmidt DK, Troup CD, Desrosiers RC. Use of simian immunodeficiency virus for vaccine research. J Med Primatol. 1990;19(3-4):395–399. [PubMed]
  • Desrosiers RC. The simian immunodeficiency viruses. Annu Rev Immunol. 1990;8:557–578. [PubMed]
  • Desrosiers RC. HIV with multiple gene deletions as a live attenuated vaccine for AIDS. AIDS Res Hum Retroviruses. 1992 Mar;8(3):411–421. [PubMed]
  • Desrosiers RC. Non-human primate models for AIDS vaccines. AIDS. 1995;9 (Suppl A):S137–S141. [PubMed]
  • Desrosiers RC, Wyand MS, Kodama T, Ringler DJ, Arthur LO, Sehgal PK, Letvin NL, King NW, Daniel MD. Vaccine protection against simian immunodeficiency virus infection. Proc Natl Acad Sci U S A. 1989 Aug;86(16):6353–6357. [PubMed]
  • Giavedoni LD, Planelles V, Haigwood NL, Ahmad S, Kluge JD, Marthas ML, Gardner MB, Luciw PA, Yilma TD. Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. J Virol. 1993 Jan;67(1):577–583. [PMC free article] [PubMed]
  • Gibbs JS, Lackner AA, Lang SM, Simon MA, Sehgal PK, Daniel MD, Desrosiers RC. Progression to AIDS in the absence of a gene for vpr or vpx. J Virol. 1995 Apr;69(4):2378–2383. [PMC free article] [PubMed]
  • Gibbs JS, Regier DA, Desrosiers RC. Construction and in vitro properties of HIV-1 mutants with deletions in "nonessential" genes. AIDS Res Hum Retroviruses. 1994 Apr;10(4):343–350. [PubMed]
  • Hirsch VM, Fuerst TR, Sutter G, Carroll MW, Yang LC, Goldstein S, Piatak M, Jr, Elkins WR, Alvord WG, Montefiori DC, et al. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol. 1996 Jun;70(6):3741–3752. [PMC free article] [PubMed]
  • Hoch J, Lang SM, Weeger M, Stahl-Hennig C, Coulibaly C, Dittmer U, Hunsmann G, Fuchs D, Müller J, Sopper S, et al. vpr deletion mutant of simian immunodeficiency virus induces AIDS in rhesus monkeys. J Virol. 1995 Aug;69(8):4807–4813. [PMC free article] [PubMed]
  • Hu SL, Abrams K, Barber GN, Moran P, Zarling JM, Langlois AJ, Kuller L, Morton WR, Benveniste RE. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science. 1992 Jan 24;255(5043):456–459. [PubMed]
  • Ilyinskii PO, Daniel MD, Simon MA, Lackner AA, Desrosiers RC. The role of upstream U3 sequences in the pathogenesis of simian immunodeficiency virus-induced AIDS in rhesus monkeys. J Virol. 1994 Sep;68(9):5933–5944. [PMC free article] [PubMed]
  • Ilyinskii PO, Desrosiers RC. Efficient transcription and replication of simian immunodeficiency virus in the absence of NF-kappaB and Sp1 binding elements. J Virol. 1996 May;70(5):3118–3126. [PMC free article] [PubMed]
  • Israel ZR, Edmonson PF, Maul DH, O'Neil SP, Mossman SP, Thiriart C, Fabry L, Van Opstal O, Bruck C, Bex F, et al. Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines. J Virol. 1994 Mar;68(3):1843–1853. [PMC free article] [PubMed]
  • Kestler HW, 3rd, Ringler DJ, Mori K, Panicali DL, Sehgal PK, Daniel MD, Desrosiers RC. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell. 1991 May 17;65(4):651–662. [PubMed]
  • Kirchhoff F, Kestler HW, 3rd, Desrosiers RC. Upstream U3 sequences in simian immunodeficiency virus are selectively deleted in vivo in the absence of an intact nef gene. J Virol. 1994 Mar;68(3):2031–2037. [PMC free article] [PubMed]
  • Lang SM, Weeger M, Stahl-Hennig C, Coulibaly C, Hunsmann G, Müller J, Müller-Hermelink H, Fuchs D, Wachter H, Daniel MM, et al. Importance of vpr for infection of rhesus monkeys with simian immunodeficiency virus. J Virol. 1993 Feb;67(2):902–912. [PMC free article] [PubMed]
  • Lewis MG, Bellah S, McKinnon K, Yalley-Ogunro J, Zack PM, Elkins WR, Desrosiers RC, Eddy GA. Titration and characterization of two rhesus-derived SIVmac challenge stocks. AIDS Res Hum Retroviruses. 1994 Feb;10(2):213–220. [PubMed]
  • Miller CJ, Marthas M, Torten J, Alexander NJ, Moore JP, Doncel GF, Hendrickx AG. Intravaginal inoculation of rhesus macaques with cell-free simian immunodeficiency virus results in persistent or transient viremia. J Virol. 1994 Oct;68(10):6391–6400. [PMC free article] [PubMed]
  • Mills KH, Page M, Kitchin P, Chan L, Jones W, Silvera P, Corcoran T, Flanagan B, Ling C, Thiriart C, et al. Immunisation of macaques with SIV env recombinants: specificity of T cell and antibody responses and evaluation of protective efficacy. J Med Primatol. 1993 Feb-May;22(2-3):104–109. [PubMed]
  • Mori K, Ringler DJ, Desrosiers RC. Restricted replication of simian immunodeficiency virus strain 239 in macrophages is determined by env but is not due to restricted entry. J Virol. 1993 May;67(5):2807–2814. [PMC free article] [PubMed]
  • Mori K, Ringler DJ, Kodama T, Desrosiers RC. Complex determinants of macrophage tropism in env of simian immunodeficiency virus. J Virol. 1992 Apr;66(4):2067–2075. [PMC free article] [PubMed]
  • Pincus SH, Cole R, Ireland R, McAtee F, Fujisawa R, Portis J. Protective efficacy of nonneutralizing monoclonal antibodies in acute infection with murine leukemia virus. J Virol. 1995 Nov;69(11):7152–7158. [PMC free article] [PubMed]
  • Schlienger K, Montefiori DC, Mancini M, Rivière Y, Tiollais P, Michel ML. Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge. J Virol. 1994 Oct;68(10):6578–6588. [PMC free article] [PubMed]
  • Shafferman A, Jahrling PB, Benveniste RE, Lewis MG, Phipps TJ, Eden-McCutchan F, Sadoff J, Eddy GA, Burke DS. Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency virus type 1 sequences. Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7126–7130. [PubMed]
  • Stahl-Hennig C, Voss G, Dittmer U, Coulibaly C, Petry H, Makoschey B, Cranage MP, Aubertin AM, Lüke W, Hunsmann G. Protection of monkeys by a split vaccine against SIVmac depends upon biological properties of the challenge virus. AIDS. 1993 Jun;7(6):787–795. [PubMed]
  • Stott EJ. Anti-cell antibody in macaques. Nature. 1991 Oct 3;353(6343):393–393. [PubMed]
  • Trono D. HIV accessory proteins: leading roles for the supporting cast. Cell. 1995 Jul 28;82(2):189–192. [PubMed]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)